Skip to content
Investors Dashboard
Contact
TwitterFacebookInstagramLinkedinYouTube
  • English
TwitterFacebookInstagramLinkedinYouTube
  • English
Pharmamar S.A
Pharmamar S.A.
Pharmamar S.APharmamar S.A
  • About PharmaMar
    • Senior Management
    • Management Team PharmaMar
    • Board of directors
    • Other Business
    • PharmaMar in the World
    • Corporate Responsibility
    • Our History
  • Patients
    • Therapeutic Indications
    • Collaboration with Patient Associations
    • Clinical trial
  • Products
    • YONDELIS®
    • Lurbinectedin
  • Science & Innovation
    • R&D and Innovation
    • Virology Unit
      • Our Vision
      • Molecular Pharmacodynamics
      • COVID-19, Clinical Development
      • COVID-19, Translational Strategy
    • Oncology Pipeline
    • Cofinanced Projects
    • Collaboration with Scientific Associations
    • Publications
    • Mechanisms of Action
    • Medical meeting presentations
  • Shareholders and Investors
    • Financial Information
      • Annual Reports
      • Interim financial information
      • Financial Statements (Zeltia)
      • Average Period of Payment to Suppliers
    • Notifications sent to CNMV
    • Share Information
      • Share Performance
      • Shares Outstanding
      • Dividends
      • Significant Shareholding & Company Owned-Stock
      • Analysts
    • Debt Obligations
    • Presentations
    • General Shareholders Meetings
    • Corporate Governance
      • Corporate Bylaws
      • General Shareholders’ Meeting Regulations
      • Shareholder Agreements
      • Board of Directors
      • Board of Directors Regulation
      • Annual Report on Corporate Governance
      • Annual Director Remuneration Report
      • Board Committees
      • Internal Regulation Governing Conduct
      • Director Selection Policy
    • Contact
    • Merger PharmaMar-Zeltia
    • General Policy of Communication
    • Sustainability Policy
    • Director’s Compensation Policy
  • Newsroom
    • Press Releases
    • Events calendar
    • Multimedia
      • Videos
      • Infographics
    • Medical meeting presentations
  • Careers
    • Benefits
    • Send us your CV
    • About PharmaMar
      • Senior Management
      • Management Team PharmaMar
      • Board of directors
      • Other Business
      • PharmaMar in the World
      • Corporate Responsibility
      • Our History
    • Patients
      • Therapeutic Indications
      • Collaboration with Patient Associations
      • Clinical trial
    • Products
      • YONDELIS®
      • Lurbinectedin
    • Science & Innovation
      • R&D and Innovation
      • Virology Unit
        • Our Vision
        • Molecular Pharmacodynamics
        • COVID-19, Clinical Development
        • COVID-19, Translational Strategy
      • Oncology Pipeline
      • Cofinanced Projects
      • Collaboration with Scientific Associations
      • Publications
      • Mechanisms of Action
      • Medical meeting presentations
    • Shareholders and Investors
      • Financial Information
        • Annual Reports
        • Interim financial information
        • Financial Statements (Zeltia)
        • Average Period of Payment to Suppliers
      • Notifications sent to CNMV
      • Share Information
        • Share Performance
        • Shares Outstanding
        • Dividends
        • Significant Shareholding & Company Owned-Stock
        • Analysts
      • Debt Obligations
      • Presentations
      • General Shareholders Meetings
      • Corporate Governance
        • Corporate Bylaws
        • General Shareholders’ Meeting Regulations
        • Shareholder Agreements
        • Board of Directors
        • Board of Directors Regulation
        • Annual Report on Corporate Governance
        • Annual Director Remuneration Report
        • Board Committees
        • Internal Regulation Governing Conduct
        • Director Selection Policy
      • Contact
      • Merger PharmaMar-Zeltia
      • General Policy of Communication
      • Sustainability Policy
      • Director’s Compensation Policy
    • Newsroom
      • Press Releases
      • Events calendar
      • Multimedia
        • Videos
        • Infographics
      • Medical meeting presentations
    • Careers
      • Benefits
      • Send us your CV

    Category Archives: Press Release

    You are here:
    1. Home
    2. Category "Press Release"

    FDA authorizes Sylentis (PharmaMar Group) to initiate Phase III trial with tivanisiran for the treatment of dry eye disease

    Press ReleaseBy admin4 March, 2021

    PharmaMar signs a new agreement with Adium to commercialize Zepzelca® (lurbinectedin) in Latin America

    Press ReleaseBy admin1 March, 2021

    PharmaMar Group reports record results for 2020

    Press ReleaseBy admin26 February, 2021

    PharmaMar enlarges its facilities to meet its upcoming business challenges

    Press ReleaseBy admin11 February, 2021

    PharmaMar presents new data on Zepzelca® (lurbinectedin) in combination with irinotecan at an oral session at (rescheduled) IASLC 2020

    Press ReleaseBy admin1 February, 2021

    GENOMICA, PharmaMar Group, announces that they have validated their PCR testing kit for saliva based sampling

    Press ReleaseBy admin28 January, 2021

    The Peer Review journal Science confirms the potent activity of PharmaMar’s plitidepsin against SARS-CoV-2

    Nota de prensa, Press ReleaseBy admin26 January, 2021

    PharmaMar will present new data for ZepzelcaTM (lurbinectedin) at rescheduled IASLC 2020

    Press ReleaseBy admin13 January, 2021

    PharmaMar signs a licensing agreement with R-Pharm to commercialize Yondelis® in Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Uzbekistan, Turkmenistan, Ukraine and Georgia

    Press ReleaseBy admin23 December, 2020

    PharmaMar and Jazz Pharmaceuticals announce results of the ATLANTIS phase III study with lurbinectedin

    Press ReleaseBy admin3 December, 2020
    12345…
    678910111213141516171819202122232425262728
    29
     Dream-Theme — truly premium WordPress themes
    Sobre PharmaMar
    Go to Top
    We use our own and third-party cookies in order to collect statistical information and to ensure the best experience on our site. If you want to accept them, click I agree.I agreeI do not acceptPrivacy policy
    You can revoke your consent any time using the Revoke consent button.Revoke consent